Hidradenitis Suppurativa

Panelists discuss how JAK inhibitors show promise for specific HS phenotypes, including patients with milder disease with inflammatory nodules, those with severe trunk/buttock disease, and systemically ill patients, and may work synergistically with IL-17 inhibitors in combination therapy for the most severe cases without additive infection risk.

Panelists discuss how secukinumab’s long-term data show sustained efficacy over 2 to 4 years with low immunogenicity, allowing patients to stop and restart therapy without loss of response—unlike TNF inhibitors—and demonstrate that some initial nonresponders improve significantly with extended treatment duration.

Panelists discuss how cutaneous adverse effects from IL-17 inhibitors, including eczematous rashes and fissures occurring in about 10% of patients, can be effectively managed with topical immunomodulators, antifungal prophylaxis, and patient counseling to maintain treatment adherence and prevent discontinuation.

Panelists discuss how 2-year bimekizumab data demonstrate that nearly half of patients achieve complete clearance (HiSCR100) with peak efficacy around 6 months, sustained improvement over time, and manageable safety concerns primarily involving cutaneous reactions like eczematous rashes that can be treated topically.

This analysis highlights the impact of dermatology consultations on HS management within acute care settings.

The FDA approved expanded indications for adalimumab-aaty (Yuflyma) and its unbranded version to include the treatment of adolescent HS and pediatric UV.

Panelists discuss how the 2 approved IL-17 inhibitors—secukinumab (IL-17A) and bimekizumab (IL-17A/F)—differ in their mechanisms, with bimekizumab potentially offering faster responses and greater impact on drainage but higher cutaneous adverse effects, while secukinumab provides a slightly better skin safety profile with slower but sustained improvement.

Panelists discuss how IL-17 emerged as a key inflammatory driver in HS pathophysiology, with IL-17 inhibitors offering strong efficacy and favorable safety profiles compared with TNF inhibitors, making them increasingly preferred as first-line biologic therapy except in patients with inflammatory bowel disease.

Panelists discuss how surgery plays a critical role in removing persistent draining sinus tunnels that don’t respond fully to anti-inflammatory medications, and explain their approach of combining biologics with surgical interventions rather than sequencing treatments, stacking therapies aggressively to achieve faster disease control.

Panelists discuss how treatment approaches vary by disease severity, with biologics becoming standard for patients with moderate to severe disease while milder cases receive antibiotics, hormonal therapies, and lifestyle interventions, emphasizing the need for flare management plans and patient education about treatment expectations.

Panelists discuss how societal factors like embarrassment and limited health care access contribute to diagnostic delays of 6 to 7 years despite HS being clinically straightforward to identify and describe the profound impact on patients’ lives beyond sterile quality of life measures, including loss of relationships, careers, and life milestones.

Panelists discuss how HS develops from a combination of genetic predisposition and environmental exposures, leading to immune-based inflammation in skin folds, and explain clinical diagnosis methods, including Hurley staging and assessment of inflammatory lesions.

These phase 3 data, released by MoonLake Immunotherapeutics, highlight week 16 results for patients with hidradenitis suppurativa using sonelokimab.

This discussion highlights 24-week findings on povorcitinib for those with moderate to severe hidradenitis suppurativa (HS).

This interview at EADV 2025 features Mona Shahriari, MD, who highlighted recent findings on the drugs icotrokinra and povorcitinib in dermatology.

A compilation of 14 trials presented as late-breaking data at EADV 2025 Congress.

These HS-OBTAIN phase 2a trial data highlight the impacts of treatment with brivekimig on patients naïve to biologics with moderate-to-severe HS.

This study highlights improvements with izokibep for HS, sustained or improved across disease measures through to Week 16.

New data reveals bimekizumab offers sustained disease control for hidradenitis suppurativa, improving patient quality of life for 3 years.

These 24-week, interim data from the phase STOP-HS study highlight the impacts of povorcitinib on patients with hidradenitis suppurativa (HS).

In this analysis, the degree to which each dermatological condition impacts biological aging was highlighted using epigenetic clocks.

Investigators explored the characteristics of pediatric-onset hidradenitis suppurativa, emphasizing the need for earlier detection to expedite diagnosis.

This analysis highlights the global prevalence of HS and some of the most significant global variations in HS prevalence.

The investigators present pooled findings from the SUNSHINE and SUNRISE trials assessing secukinumab therapy for HS.

This cohort study suggests that patients with HS treated with adalimumab have an increased risk of infection compared to those with psoriasis.